Abstract
Biomarker development is a major research theme in cancer proteomics. Cancer is a genetically and clinically diverse disease, and biomarkers for risk stratification therapy are urgently required. A considerable number of biomarker candidates have been discovered by proteomics, and over the last decade proteomics modalities have been developed to identify promising candidates. Validation studies involving hundreds of samples in independent cohorts is the next challenge to prove the clinical utility of any discovered biomarker candidates. Here, we review our efforts directed toward tissue biomarker development using a proteomics approach. With the aim of developing a prognostic biomarker for gastrointestinal stromal tumor (GIST), we examined the protein expression profiles of primary tumors from 17 GIST patients with different risks of recurrence and prognosis after surgery. Through a comparative study using two-dimensional difference gel electrophoresis and mass spectrometry, we found that overexpression of pfetin was specific to GIST patients with a low risk of metastasis and a favorable prognosis after surgery. Using immunohistochemistry, we examined pfetin expression in 422 additional cases of GIST at four hospitals, and confirmed that GIST patients with pfetin-positive primary tumors had a significantly favorable prognosis in all four cohorts. Moreover, the other research group independently validated the prognostic significance of pfetin in 62 cases of GIST at two hospitals. Pfetin was found to be an independent prognostic factor with significant prognostic utility in all risk classification groups, which are based on tumor size and mitosis status. In addition to pfetin, we also identified DDX39 as a biomarker of unfavorable prognosis using a proteomics approach, and KCTD10 as a marker of favorable prognosis using a knowledge-based approach. Our experience demonstrates the utility of proteomics for biomarker discovery, and the possible clinical application of pfetin for risk stratification therapy in GIST.
Highlights
Cancer is a genetically and clinically diverse disease, and personally optimized therapy is required for optimization of the clinical outcome
Among the 25 proteins, we further focused on one protein, pfetin, which was detected in 8 protein spots that showed higher intensity in gastrointestinal stromal tumor (GIST) patients with a favorable prognosis
Using western blotting and immunohistochemistry, we confirmed the correlation between higher expression of pfetin and a favorable prognosis in the GIST cases, which we examined by 2D-DIGE [8]
Summary
Cancer is a genetically and clinically diverse disease, and personally optimized therapy is required for optimization of the clinical outcome. As unavoidable confounding factors are often associated with any cancer biomarker study [5,6], the risk of false positive discovery cannot be avoided when thousands of proteins are screened in a small number of samples using modern proteomics modalities. We have been conducting cancer proteomics studies for discovery of biomarkers, and have used two-dimensional difference gel electrophoresis (2D-DIGE) to create protein expression profiles [30,31].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
